DNA
Ginkgo Bioworks Holdings, Inc. [DNA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
DNA Stock Summary
Top 10 Correlated ETFs
DNA
Top 10 Correlated Stocks
DNA
In the News
DNA Financial details
Company Rating
Neutral
Market Cap
2.17B
Income
-892.87M
Revenue
251.46M
Book val./share
0.55
Cash/share
0.48
Dividend
-
Dividend %
-
Employees
1.22K
Optionable
No
Shortable
Yes
Earnings
29 Feb 2024
P/E
-3.44
Forward P/E
-
PEG
0.55
P/S
10.16
P/B
2.35
P/C
1.78
P/FCF
-7.89
Quick Ratio
6.6
Current Ratio
6.78
Debt / Equity
0.22
LT Debt / Equity
0.2
-
-
EPS (TTM)
-0.47
EPS next Y
-
EPS next Q
-
EPS this Y
-63.2%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
41.64%
Revenue last 5Y
35.93%
Revenue Q/Q
-37.3%
EPS Q/Q
-31.25%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
58.56%
Inst Trans
0.94%
ROA
-42%
ROE
-56%
ROC
-0.5%
Gross Margin
75%
Oper. Margin
-292%
Profit Margin
-272%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.993-2.545
52W High
-
52W Low
-
RSI
34
Rel Volume
1.51
Avg Volume
22.47M
Volume
33.99M
Perf Week
-18.64%
Perf Month
-29.98%
Perf Quarter
-36.72%
Perf Half Y
-50.9%
-
-
-
-
Beta
1.357
-
-
Volatility
0.05%, 0.09%
Prev Close
-7.6%
Price
0.8543
Change
-1.35%
DNA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.04 | 0.06 | 0.19 | 0.28 | 0.13 | |
| Net income per share | -0.08 | -0.1 | -1.14 | -1.25 | -0.46 | |
| Operating cash flow per share | -0.03 | -0.11 | -0.16 | -0.15 | -0.15 | |
| Free cash flow per share | -0.05 | -0.15 | -0.19 | -0.18 | -0.17 | |
| Cash per share | 0.33 | 0.3 | 0.96 | 0.78 | 0.49 | |
| Book value per share | 0.33 | 0.36 | 0.93 | 1.03 | 0.56 | |
| Tangible book value per share | 0.33 | 0.36 | 0.95 | 0.93 | 0.5 | |
| Share holders equity per share | 0.33 | 0.36 | 0.93 | 1.03 | 0.56 | |
| Interest debt per share | 0 | 0.02 | 0.02 | 0.26 | 0.12 | |
| Market cap | 15.03B | 13.04B | 13.39B | 2.84B | 3.29B | |
| Enterprise value | 14.53B | 12.68B | 11.86B | 1.96B | 2.58B | |
| P/E ratio | -125.39 | -102.91 | -7.29 | -1.35 | -3.68 | |
| Price to sales ratio | 277.37 | 170.12 | 42.67 | 5.94 | 13.07 | |
| POCF ratio | -336.49 | -96.01 | -52.76 | -11.25 | -11.12 | |
| PFCF ratio | -224.71 | -67.34 | -43.15 | -9.32 | -9.77 | |
| P/B Ratio | 30.48 | 28.26 | 8.9 | 1.63 | 3 | |
| PTB ratio | 30.48 | 28.26 | 8.9 | 1.63 | 3 | |
| EV to sales | 268.23 | 165.37 | 37.8 | 4.11 | 10.26 | |
| Enterprise value over EBITDA | -179.32 | -117.91 | -6.32 | -0.9 | -4.29 | |
| EV to operating cash flow | -325.4 | -93.33 | -46.74 | -7.79 | -8.73 | |
| EV to free cash flow | -217.3 | -65.46 | -38.23 | -6.45 | -7.67 | |
| Earnings yield | -0.01 | -0.01 | -0.14 | -0.74 | -0.27 | |
| Free cash flow yield | 0 | -0.01 | -0.02 | -0.11 | -0.1 | |
| Debt to equity | 0 | 0.04 | 0.02 | 0.25 | 0.22 | |
| Debt to assets | 0 | 0.03 | 0.01 | 0.17 | 0.15 | |
| Net debt to EBITDA | 6.11 | 3.38 | 0.81 | 0.4 | 1.18 | |
| Current ratio | 12.77 | 5.83 | 12.79 | 8.38 | 6.11 | |
| Interest coverage | -29.57 | -57.45 | -770.53 | -20.84K | -7.23K | |
| Income quality | 0.37 | 1.07 | 0.14 | 0.12 | 0.33 | |
| Dividend Yield | 0 | 0 | 0.11 | 0 | 0 | |
| Payout ratio | 0 | 0 | -0.82 | 0 | 0 | |
| Sales general and administrative to revenue | 0.54 | 0.5 | 2.75 | 2.99 | 1.53 | |
| Research and developement to revenue | 1.78 | 2.08 | 3.66 | 2.2 | 2.09 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.02 | 0.07 | 0.08 | |
| Capex to operating cash flow | 0.5 | 0.43 | 0.22 | 0.21 | 0.14 | |
| Capex to revenue | -0.41 | -0.75 | -0.18 | -0.11 | -0.16 | |
| Capex to depreciation | -2.07 | -4.17 | -1.94 | -1.18 | -0.57 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 5.12 | 4.04 | 0.91 | |
| Graham number | 0.78 | 0.89 | 4.89 | 5.4 | 2.41 | |
| ROIC | -0.15 | -0.28 | -1.18 | -0.85 | -0.43 | |
| Return on tangible assets | -0.17 | -0.19 | -0.91 | -0.89 | -0.58 | |
| Graham Net | 0.21 | 0.15 | 0.72 | 0.34 | 0.21 | |
| Working capital | 471.85M | 353.32M | 1.59B | 1.28B | 837.89M | |
| Tangible asset value | 496.15M | 464.9M | 1.52B | 1.57B | 965.17M | |
| Net current asset value | 316.46M | 221.44M | 1.22B | 647.04M | 433.56M | |
| Invested capital | 0 | 0.04 | 0.02 | 0.25 | 0.22 | |
| Average receivables | 0 | 15.93M | 87.04M | 116.18M | 57.1M | |
| Average payables | 0 | 8.17M | 11.04M | 9.32M | 9.89M | |
| Average inventory | 0 | 1.37M | 3.05M | 3.86M | 2.21M | |
| Days sales outstanding | 51.72 | 115.1 | 174.34 | 63.01 | 46.07 | |
| Days payables outstanding | 0 | 324.83 | 23.05 | 18.68 | 31.27 | |
| Days of inventory on hand | 0 | 63.97 | 9.46 | 7.8 | 0.15 | |
| Receivables turnover | 7.06 | 3.17 | 2.09 | 5.79 | 7.92 | |
| Payables turnover | 0 | 1.12 | 15.84 | 19.54 | 11.67 | |
| Inventory turnover | 0 | 5.71 | 38.58 | 46.8 | 2.37K | |
| ROE | -0.24 | -0.27 | -1.22 | -1.21 | -0.81 | |
| Capex per share | -0.01 | -0.04 | -0.04 | -0.03 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.05 | 0.04 | 0.04 | 0.03 | 0.02 | |
| Net income per share | -0.09 | -0.11 | -0.09 | -0.16 | -0.11 | |
| Operating cash flow per share | -0.06 | -0.05 | -0.04 | -0.04 | -0.02 | |
| Free cash flow per share | -0.07 | -0.06 | -0.05 | -0.04 | -0.03 | |
| Cash per share | 0.71 | 0.63 | 0.57 | 0.54 | 0.48 | |
| Book value per share | 0.94 | 0.84 | 0.78 | 0.64 | 0.55 | |
| Tangible book value per share | 0.84 | 0.75 | 0.69 | 0.56 | 0.49 | |
| Share holders equity per share | 0.94 | 0.84 | 0.78 | 0.64 | 0.55 | |
| Interest debt per share | 0.25 | 0.21 | 0.21 | 0.21 | 0.12 | |
| Market cap | 3.13B | 2.55B | 3.6B | 3.53B | 3.34B | |
| Enterprise value | 2.26B | 1.74B | 2.9B | 2.89B | 2.64B | |
| P/E ratio | -4.5 | -3.11 | -5.19 | -2.91 | -3.95 | |
| Price to sales ratio | 31.9 | 31.56 | 44.64 | 63.7 | 96.17 | |
| POCF ratio | -29.94 | -28.12 | -48.91 | -48.01 | -68.84 | |
| PFCF ratio | -24.05 | -23.15 | -41.3 | -45.31 | -64.28 | |
| P/B Ratio | 1.81 | 1.58 | 2.39 | 2.82 | 3.05 | |
| PTB ratio | 1.81 | 1.58 | 2.39 | 2.82 | 3.05 | |
| EV to sales | 23.01 | 21.62 | 36.01 | 52.05 | 75.82 | |
| Enterprise value over EBITDA | -9.66 | -9.11 | -18.21 | -73.89 | -18.61 | |
| EV to operating cash flow | -21.6 | -19.26 | -39.46 | -39.23 | -54.27 | |
| EV to free cash flow | -17.35 | -15.86 | -33.32 | -37.02 | -50.68 | |
| Earnings yield | -0.06 | -0.08 | -0.05 | -0.09 | -0.06 | |
| Free cash flow yield | -0.04 | -0.04 | -0.02 | -0.02 | -0.02 | |
| Debt to equity | 0.25 | 0.25 | 0.27 | 0.32 | 0.22 | |
| Debt to assets | 0.17 | 0.17 | 0.18 | 0.2 | 0.15 | |
| Net debt to EBITDA | 3.73 | 4.19 | 4.36 | 16.53 | 4.99 | |
| Current ratio | 8.38 | 6.92 | 7.49 | 6.78 | 6.11 | |
| Interest coverage | -17.96 | 37.9 | 0 | 0 | -1.66K | |
| Income quality | 0.6 | 0.44 | 0.42 | 0.24 | 0.23 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.24 | 1.38 | 1.27 | 1.48 | 2.57 | |
| Research and developement to revenue | 1.84 | 2.02 | 1.79 | 2.83 | 3.1 | |
| Intangibles to total assets | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | |
| Capex to operating cash flow | 0.24 | 0.21 | 0.18 | 0.06 | 0.07 | |
| Capex to revenue | -0.26 | -0.24 | -0.17 | -0.08 | -0.1 | |
| Capex to depreciation | -1.62 | -1.03 | -0.74 | -0.21 | -0.27 | |
| Stock based compensation to revenue | 1.1 | 0.9 | 0.76 | 0.95 | 1.23 | |
| Graham number | 1.41 | 1.42 | 1.25 | 1.5 | 1.16 | |
| ROIC | -0.08 | -0.09 | -0.08 | -0.14 | -0.1 | |
| Return on tangible assets | -0.07 | -0.09 | -0.08 | -0.16 | -0.14 | |
| Graham Net | 0.31 | 0.24 | 0.19 | 0.17 | 0.2 | |
| Working capital | 1.28B | 1.14B | 1.06B | 973.38M | 837.89M | |
| Tangible asset value | 1.57B | 1.44B | 1.34B | 1.09B | 965.17M | |
| Net current asset value | 647.04M | 517.68M | 435.04M | 368.14M | 433.56M | |
| Invested capital | 0.25 | 0.25 | 0.27 | 0.32 | 0.22 | |
| Average receivables | 99.11M | 83.65M | 76.88M | 66.03M | 47.44M | |
| Average payables | 10.89M | 16.01M | 17.6M | 12.19M | 10.04M | |
| Average inventory | 5.11M | 3.44M | 1.45M | 230.5K | 58K | |
| Days sales outstanding | 75.51 | 94.62 | 76.99 | 102.52 | 82.19 | |
| Days payables outstanding | 31.13 | 86.77 | 67.79 | 139.79 | 52.61 | |
| Days of inventory on hand | 13 | 10.09 | 1.94 | 0.91 | 0.26 | |
| Receivables turnover | 1.19 | 0.95 | 1.17 | 0.88 | 1.1 | |
| Payables turnover | 2.89 | 1.04 | 1.33 | 0.64 | 1.71 | |
| Inventory turnover | 6.92 | 8.92 | 46.28 | 98.9 | 346.7 | |
| ROE | -0.1 | -0.13 | -0.12 | -0.24 | -0.19 | |
| Capex per share | -0.01 | -0.01 | -0.01 | 0 | 0 |
DNA Frequently Asked Questions
What is Ginkgo Bioworks Holdings, Inc. stock symbol ?
Ginkgo Bioworks Holdings, Inc. is a US stock , located in Boston of Ma and trading under the symbol DNA
What is Ginkgo Bioworks Holdings, Inc. stock quote today ?
Ginkgo Bioworks Holdings, Inc. stock price is $0.8543 today.
Is Ginkgo Bioworks Holdings, Inc. stock public?
Yes, Ginkgo Bioworks Holdings, Inc. is a publicly traded company.
Company Profile
- Volume Average 22.47M
- Market Capitalization 2.17B
- Employee 1.22K
- CEO Dr. Jason Kelly
- Headquarters Boston,MA,US
- IPO Date 2021-04-19
-
Website
https://www.ginkgobioworks.com 
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
